Pharma major Wockhardt Tuesday got the US Food and Drug Administration's (USFDA) tentative approval for marketing Tamsulosin Hydrochloride capsules.
Tamsulosin is being used for treating non-cancerous enlargement of prostate, technically called benign prostatic hyperplasia.
Tamsulosin is the generic name for the brand Flomax, developed by Japanese drug major Astellas and marketed in the US by Boehringer Ingelheim.
The patent on this product will expire April 27, 2010 and Wockhardt will launch the product immediately thereafter, said a company statement.
No other company has got the USFDA sanction for the Tamsulosin capsule of 0.4mg strength, a company spokesperson claimed.
He said the total market for Tamsulosin capsules in the US is about $1,650 million.